medication in the United States, with more than 11 million prescriptions. Fluticasone/salmeterol is indicated for the treatment of asthma. Fluticasone, a ...

Last year saw a key development in the US respiratory diseases market when Mylan finally launched its generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol).

Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated ...

The main patent on Advair (fluticasone+salmeterol) expired as long ago as 2010, while the patent on GSK’s Diskus inhaler expired in 2016. But Mylan became the first of a group of potential ...

Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare ...

BACKGROUND The potential for long term adverse effects from inhaled corticosteroids relates to their systemic absorption, usually assessed from proxy markers in short term studies. When fluticasone ...

The dose is represented with two microgram (mcg) numbers and written as fluticasone mcg/salmeterol mcg per puff. The Diskus is available in doses of 100/50, 250/50, or 500/50, and the HFA is ...

One hundred sixty-four patients who were taking regular inhaled salmeterol and 382 patients who were not taking salmeterol were identified. Patients were investigated and defined on the basis of ...

The Inhalation and Nasal Spray Generic Drugs Market is taking a deep breath and preparing for a significant upswing. Expert ...

After hours: October 21 at 7:53 PM EDT ...